Edition:
United Kingdom

Abcam PLC (ABCA.L)

ABCA.L on London Stock Exchange

1,411.00GBp
17 May 2019
Change (% chg)

-2.00 (-0.14%)
Prev Close
1,413.00
Open
1,375.00
Day's High
1,413.00
Day's Low
1,375.00
Volume
277,568
Avg. Vol
433,382
52-wk High
1,643.80
52-wk Low
1,006.00

Summary

Name Age Since Current Position

Peter Allen

59 2018 Non-Executive Chairman of the Board

Alan Hirzel

2014 Chief Executive Officer, Executive Director

Jonathan Milner

2018 Non-Executive Deputy Chairman of the Board

Gavin Wood

47 2016 Chief Financial Officer, Executive Director

Marc Perkins

2019 Interim Company Secretary

Giles Kerr

57 2018 Non-Executive Director

Mara Aspinall

55 2018 Non-Executive Independent Director

Susan Harris

55 2014 Non-Executive Independent Director

Louise Patten

64 2018 Senior Independent Non-Executive Director

James Staveley

2019 Vice President - Investor Relations

Biographies

Name Description

Peter Allen

Mr. Peter Vance Allen is Non-Executive Chairman of the Board of the Company. Peter has over 20 years’ experience as an executive director, non-executive director and chairman in a wide range of life science companies playing a significant role in their growth. He spent three years as Chairman of Proximagen Neurosciences plc (2009-2012), six years at ProStaken Group plc as Chairman (2007–2013) and interim CEO (2010–2011) and twelve years at Celltech Group plc (1992–2004) as CFO and Deputy CEO. Peter is currently Non-Executive Chairman of AIM listed Advanced Medical Solutions plc, Clinigen plc and Diurnal plc and privately-owned Oxford Nanopore Technologies Ltd. He is a Non-Executive Director of Istesso Ltd. A chartered accountant by background, Peter is an experienced chairman and board member and has substantial experience in M&A, international growth, fundraising and investor relations, as well as the commercialisation of intellectual property.

Alan Hirzel

Mr. Alan Thomas Hirzel is Chief Executive Officer, Executive Director of Abcam Plc. Alan joined Abcam as Chief Marketing Officer in 2013 to implement the growth strategy he defined with the Board and CEO. In 2014 he became CEO and succeeded Abcam founder Jonathan Milner. Prior to joining Abcam, Alan spent 14 years with Bain & Company helping companies grow organically and through acquisition. Earlier in his career, he led product innovation efforts for several brands at Kraft Foods. He trained as a life science researcher with BS and MS degrees from Cornell University. He also has a passion for social enterprise and was involved in establishing two social venture philanthropy organisations in the UK and later acted as a Trustee for the National Citizen’s Service Trust. Alan brings to the Abcam Board an impressive combination of a strong scientific background, global business and leadership experience as well as strong consumer knowledge. Alan has a keen focus on the consumer, helping Abcam’s strategic vision to be a successful global business by placing the customer at the heart of it.

Jonathan Milner

Dr. Jonathan Simon Milner, Ph.D. is Non-Executive Deputy Chairman of the Board of Abcam Plc. Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high-quality antibodies to support protein interaction studies and in 1998 founded Abcam with Dr David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of The Evolution Education Trust, HealX, Repositive Ltd, Syndicate Room Group Ltd and Elpis Biomedical Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd and CamAllergy Ltd. Jonathan holds an Executive Director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP, and is a member of the advisory panel of Cambridge Innovation Capital plc. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three AIM IPOs.

Gavin Wood

Mr. Gavin Hilary James Wood, BA (Hons) ACA is Chief Financial Officer, Executive Director of the Company. Gavin is a chartered accountant who started his career in practice in London before moving to Grant Thornton’s Thames Valley office. After five years in practice, Gavin moved to Unipart Group of Companies, where he had a number of roles of increasing responsibility before moving into the life sciences sector. He spent nearly a decade at Nasdaq-quoted Affymetrix, Inc. in a variety of roles, most recently as Executive Vice President and Chief Financial Officer leading the global finance and information technology functions. Gavin has over 20 years’ experience as an accounting professional with broad and international exposure in a number of sectors and roles including corporate, statutory and operational accounting, project management and investor relations.

Marc Perkins

Giles Kerr

Mr. Giles Francis Bertram Kerr is Non-Executive Director of the Company. Giles has extensive experience as an executive and non-executive Director in a wide range of public and private organisations. He recently stepped down as Finance Director of Oxford University, a position he had held since 2005. He remains a non-executive Director of Arix Biosciences plc, Adaptimmune Therapeutics plc, Senior plc, PayPoint plc as well as Oxford Sciences Innovation. From 1990 to 2004 Giles held a number of roles at Amersham plc, including Group Finance Director. Giles is a graduate in Economics from the University of York and a Chartered Accountant.

Mara Aspinall

Ms. Mara Glickman Aspinall is Non-Executive Independent Director of the Company. Mara is CEO of Heath Catalysts Group and Managing Director of BlueStone Venture Partners. Previously, Mara was President and CEO of Ventana Medical Systems/Roche Tissue Diagnostics, leading the company to increased market leadership worldwide and primacy in companion diagnostics. Mara spent twelve years at Genzyme Corporation (now part of Sanofi) as President of Genzyme Genetics and Genzyme Pharmaceuticals. She is co-founder of the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the only institution dedicated to the study of diagnostics as an independent discipline. She is a Fellow of the American Institute for Medical and Biological Engineering. Mara is a Director of Allscripts Healthcare Solutions Inc, Castle Biosciences, Blue Cross Blue Shield Arizona, OraSure Technologies and 3Scan Inc. Mara has considerable international experience in the biotechnology and diagnostics industries with public and private companies. Mara’s specific focus areas are acquisition integration, global manufacturing, quality systems and strategic marketing.

Susan Harris

Ms. Susan Elizabeth (Sue) Harris is Non-Executive Independent Director of the Company. A chemist by training, Sue’s career began at Ford, before moving to oil company Amerada Hess. She subsequently held senior roles at Marks & Spencer plc across finance, latterly as Head of Corporate Development and Group Treasurer. She was Managing Director Finance at Standard Life, where she led the process to float the Group. She was Finance Director of Cheltenham and Gloucester, Lloyds Banking Group’s Retail Bank and Group Finance and Group Audit Director. Previously Sue was a Non-Executive Director of St. James’s Place and Bank of Ireland UK, a member of the audit and remuneration committees of the British Bankers’ Association, Chair of Trustees for KCP Youth and chaired the finance and audit committees of Mencap. Sue is Chair of the Audit and Assurance Council and a member of the Codes and Standards Committee of the Financial Reporting Council, a Non-Executive Director of Schroder & Co. Limited and of Barclays Pension Funds Trustees Limited. With over 30 years’ of financial, commercial and corporate board experience as well as her scientific background, Sue brings a wealth of skills that strengthen the Abcam Board in its growth strategy.

Louise Patten

Ms. Louise A. V. C. Patten is Senior Independent Non-Executive Director of the Company. Having started her career in corporate and investment banking, Louise moved into management consultancy and became a Board Director of the Hilton Group. Since then she has served on a succession of multi-national listed company boards for more than 20 years as a non-executive director, a senior independent director, a remuneration committee chairman and a company chairman at organisations including the retailers Marks & Spencer plc, GUS plc and Somerfield plc. Louise is currently a Non-Executive Director of Intu Properties plc, a Senior Advisor to Bain & Company and a Non-Executive Director of Arthur J. Gallagher Insurance Brokers Limited. Louise’s highly recognised career in business, with her extensive board and corporate governance experience, brings Abcam the knowledge and proficiency required to support its strategic growth plans and, whilst doing this, ensures that the Abcam Board is led by a robust governance framework.

James Staveley

Basic Compensation

Name Fiscal Year Total

Peter Allen

9,000

Alan Hirzel

1,788,000

Jonathan Milner

70,000

Gavin Wood

666,000

Marc Perkins

--

Giles Kerr

--

Mara Aspinall

70,000

Susan Harris

70,000

Louise Patten

129,000

James Staveley

--
As Of  30 Jun 2018